A Research Guide for
PAH

PAH is usually first suspected based on symptoms (progressive shortness of breath, fatigue) or incidental findings on tests done for other reasons.

• Transthoracic echocardiogram (TTE) — The first-line screening test. Estimates right ventricular systolic pressure (RVSP) from the tricuspid regurgitation jet velocity. An estimated RVSP >40 mmHg or tricuspid regurgitation velocity >2.8 m/s warrants further evaluation. However, echo can overestimate or underestimate pressures by 10–15 mmHg.
• Blood tests — NT-proBNP or BNP (markers of heart strain), autoimmune panel (ANA, anti-Scl-70, anti-centromere for scleroderma screening), HIV test, liver function tests, thyroid function.
• Pulmonary function tests (PFTs) — To evaluate for underlying lung disease. A reduced DLCO (diffusing capacity) with preserved lung volumes can be a clue to pulmonary vascular disease.
• CT scan of the chest — High-resolution CT to evaluate for interstitial lung disease. CT pulmonary angiography to evaluate for chronic blood clots (CTEPH).
• V/Q scan (ventilation/perfusion scan) — The gold standard to screen for CTEPH. More sensitive than CT angiography for chronic thromboembolic disease. Should be done in every PH workup.

Right heart catheterization (RHC) is the only test that can definitively diagnose PAH. A thin catheter is threaded through a large vein (usually in the neck or groin) into the right side of the heart and pulmonary arteries. It directly measures:

• Mean pulmonary artery pressure (mPAP) — Normal is 14 ± 3 mmHg. PH is defined as mPAP >20 mmHg (updated from >25 mmHg by the 6th WSPH in 2018).
• Pulmonary artery wedge pressure (PAWP) — Reflects left-sided filling pressures. PAWP ≤15 mmHg means pre-capillary PH (consistent with PAH). PAWP >15 mmHg suggests left heart disease (Group 2).
• Pulmonary vascular resistance (PVR) — Must be >2 Wood units for PAH diagnosis. Calculated from (mPAP − PAWP) ÷ cardiac output.
• Cardiac output and cardiac index — Measures how well the right heart is pumping. A cardiac index <2.0 L/min/m² indicates severe compromise.

What the procedure is like: RHC typically takes 30–60 minutes. It is done under local anesthesia with mild sedation. Most patients describe mild pressure or discomfort but not significant pain. Complications are rare (<1%) at experienced centers. You may go home the same day or stay overnight.

During the right heart catheterization, your doctor should perform acute vasoreactivity testing. This involves inhaling a short-acting vasodilator (usually inhaled nitric oxide, or sometimes IV epoprostenol or IV adenosine) to see if the pulmonary arteries relax.

• A positive response is defined as a drop in mPAP of ≥10 mmHg to an absolute mPAP of ≤40 mmHg, with maintained or improved cardiac output.
• Only about 5–10% of idiopathic PAH patients are true vasoreactive responders.
• True responders can be treated with high-dose calcium channel blockers (nifedipine, diltiazem, or amlodipine) — a much simpler treatment. They must be followed closely, as response can wane over time.
• Non-responders (the vast majority) should NOT receive calcium channel blockers for PAH. They are started on combination therapy with ERAs, PDE5 inhibitors, and/or prostacyclin pathway agents based on risk stratification.

Important: Vasoreactivity testing should only be done in patients with idiopathic, heritable, or drug-induced PAH. It should not be performed in patients with very low cardiac output, and it is not recommended for CTD-PAH or other associated forms of PAH.

Once PAH is confirmed, your team will assess your risk — essentially predicting how likely the disease is to worsen over the next year. This determines how aggressively treatment should be started and escalated.

The major risk tools used are:

• ESC/ERS 4-strata model — Uses WHO functional class, 6-minute walk distance, NT-proBNP, and imaging to categorize risk as low, intermediate-low, intermediate-high, or high.
• REVEAL 2.0 — A US-based calculator that assigns a score using 13 variables including demographics, hemodynamics, labs, and functional class. Higher scores = higher risk. A simplified version, REVEAL Lite 2.0, uses 6 non-invasive variables and can be calculated at the bedside without catheterization data.
• COMPERA 2.0 — A European registry-based tool particularly useful at follow-up assessment.

What the risk levels mean:

• Low risk: Estimated 1-year mortality <5%. Goal of treatment. Can usually manage with oral combination therapy.
• Intermediate-low risk: 1-year mortality 5–10%. Consider adding therapy or sotatercept.
• Intermediate-high risk: 1-year mortality 10–20%. Requires aggressive triple therapy including parenteral prostacyclin. Consider sotatercept.
• High risk: 1-year mortality >20%. Needs urgent treatment escalation, parenteral prostacyclin, and early transplant referral.

• What were the exact numbers from my right heart catheterization (mPAP, PAWP, PVR, cardiac output)?
• Was vasoreactivity testing performed? Was I positive or negative?
• What is my current risk level using the 4-strata model and/or REVEAL 2.0?
• Have all other causes of PH been ruled out (CTEPH, left heart disease, lung disease)?
• Do I need any additional testing (autoimmune panel, HIV test, V/Q scan, sleep study)?
• How often will I be reassessed with 6-minute walk tests and blood work?
• Should I be seen at a specialized PH center for ongoing care?

Endothelin-1 is a potent vasoconstrictor (blood vessel tightener) and promoter of cell growth that is overproduced in PAH. ERAs block its effects.

Key side effects: Peripheral edema, nasal congestion, anemia, and potential liver toxicity (especially bosentan). All ERAs are strictly contraindicated in pregnancy (teratogenic) — reliable contraception is mandatory. Monthly pregnancy testing is required for women of childbearing potential.

These drugs enhance the nitric oxide signaling pathway, which is impaired in PAH. Nitric oxide is a natural vasodilator produced in the blood vessel lining.

Opsynvi (macitentan + tadalafil) — FDA approved March 2024. The first single-pill combination of an ERA and PDE5 inhibitor for PAH. Simplifies treatment by reducing pill burden. Same components as separate pills but in one tablet.

Key side effects: Headache, flushing, nasal congestion, muscle aches, low blood pressure. Riociguat requires careful dose titration starting at 0.5 mg. Do not take PDE5 inhibitors with nitrate medications (risk of dangerous hypotension).

Prostacyclin is a natural substance that relaxes blood vessels, prevents blood clots, and inhibits abnormal cell growth. In PAH, prostacyclin production is reduced. These drugs replace or enhance prostacyclin signaling.

Key side effects (class-wide): Jaw pain, headache, flushing, diarrhea, nausea, muscle/joint aches, injection site pain (SC treprostinil). These are often most pronounced during dose titration and may improve over time. For IV prostacyclins, central line infections and pump malfunctions are additional risks.

Sotatercept is a first-in-class activin signaling inhibitor that was FDA-approved in March 2024. It represents the most significant advance in PAH treatment in over 15 years and the first truly new drug class since prostacyclins.

How it works: Unlike all other PAH drugs that primarily relax blood vessels, sotatercept addresses the underlying disease process. It acts as a “ligand trap” for activin A and other TGF-β superfamily proteins that drive the abnormal cell growth and thickening of pulmonary artery walls. By restoring the balance between growth-promoting and growth-inhibiting signals, it can actually reverse vascular remodeling.

Administration: Subcutaneous injection every 3 weeks. Starting dose 0.3 mg/kg, titrated to 0.7 mg/kg. Can be given at home or in clinic.

Key trial results:

• STELLAR trial (NCT04576988) — Sotatercept added to background therapy (at least one PAH drug) in WHO FC II–III patients improved 6-minute walk distance by 40.8 meters vs placebo, significantly reduced PVR, improved NT-proBNP, improved WHO functional class, and delayed time to clinical worsening. The magnitude of benefit exceeded any prior PAH drug added to background therapy.
• ZENITH trial (NCT04896008) — Evaluated sotatercept in higher-risk patients (WHO FC III–IV on ≥double combination therapy, N=172 randomized) and showed a 76% reduction (HR 0.24) in the composite of death, lung transplant, or hospitalization for worsening PAH. ZENITH was stopped early in November 2024 because the benefit was so clear. On October 27, 2025, the FDA formally updated the Winrevair label based on ZENITH to add reducing the risk of clinical worsening events (hospitalization for PAH, lung transplant, and death) — confirming the benefit in sicker patients (Merck/FDA, October 2025).
• HYPERION trial (NCT04811092) — Evaluated sotatercept plus combination therapy as first-line treatment in recently diagnosed PAH patients (N=320) on background therapy. It met its primary endpoint — time to clinical worsening was markedly reduced (hazard ratio 0.24, about a 76% lower risk of a worsening event; P<0.001), with events in 10.6% on sotatercept vs 36.9% on placebo. Enrollment was closed early because of accumulating external evidence (STELLAR and ZENITH), but the trial reported a clearly positive result (published in NEJM, 2025), supporting sotatercept use in newly diagnosed patients.
• SOTERIA (NCT04796337) — Open-label extension study of STELLAR. Confirmed durability of sotatercept benefit at 2+ years with continued improvements in 6MWD, PVR, and functional class. Supports long-term safety and sustained efficacy.

EMA approval: The European Medicines Agency approved sotatercept in August 2024, making it available across all 27 EU member states.

Key side effects: Increased hemoglobin/erythrocytosis (the most common effect — blood counts must be monitored), nosebleeds (epistaxis), telangiectasias (small dilated blood vessels on the skin), dizziness, headache. There are signals for potential effects on bleeding and thrombocytopenia. Sotatercept is distributed through a Risk Evaluation and Mitigation Strategy (REMS) program due to teratogenicity risk.

Practical considerations: Sotatercept is added to existing background therapy — it is NOT used as monotherapy. Regular blood count monitoring is required (hemoglobin, platelets). The cost is significant, and access may require prior authorization and specialty pharmacy coordination.

These are typical adult doses and monitoring numbers taken from the US FDA labels and the ESC/ERS 2022 guideline. Your PH team individualizes every dose to your weight, kidney and liver function, blood pressure, and how you tolerate the medicine — print this table and ask which numbers apply to you.

Why the numbers matter: Two of the most important safety numbers in PAH are on this table — the bosentan liver-enzyme stop rule (reduce or stop above 3 times the upper normal limit) and the sotatercept hemoglobin hold rule (hold above 16 g/dL). Ask your team to tell you your own most recent values.

Modern PAH care is built on synergy: each drug class corrects a different broken pathway in the diseased lung arteries, so combining them produces a combination benefit that is larger than any one drug alone. This is why guidelines now start most patients on two or three drugs together rather than one at a time.

• ERA + PDE5 inhibitor (the base pair): The endothelin blocker (ambrisentan/macitentan) and the nitric-oxide-pathway drug (tadalafil/sildenafil) act on separate signals. The AMBITION trial (NCT01178073) showed this synergistic pair cut the risk of clinical failure by about 50% versus one drug alone.
• Adding a prostacyclin pathway agent (the third pathway): Selexipag or inhaled/IV treprostinil adds the prostacyclin signal on top. In GRIPHON, adding selexipag to background therapy reduced worsening events by 40% — a stacking benefit on top of the base pair.
• Adding sotatercept (a fourth, disease-modifying pathway): Sotatercept works on the activin pathway to reverse vessel thickening, so its benefit amplifies the vessel-relaxing drugs rather than duplicating them. In STELLAR and ZENITH it added benefit on top of two or three background drugs.

The practical takeaway: because these effects combine rather than overlap, reaching low-risk status usually means being on the right combination, not simply a higher dose of one drug.

• Supplemental oxygen — Prescribed when blood oxygen levels fall below 90% at rest or during exertion. Especially important during air travel (cabin pressure equivalent to 6,000–8,000 ft altitude) and at high elevations. Utah patients living at altitude (~4,300 ft in Salt Lake City) may need oxygen at lower thresholds.
• Diuretics — Essential for managing fluid retention (edema). Furosemide (Lasix) is most common. Daily weight monitoring helps guide diuretic dosing — report weight gain of >2 lbs in a day or >5 lbs in a week.
• Anticoagulation — No longer routinely recommended for all PAH patients. May be considered in idiopathic PAH. Generally avoided in CTD-PAH due to bleeding risk, especially in scleroderma with GI involvement.
• Supervised exercise training — Evidence from multiple studies shows that supervised, PAH-specific exercise programs improve 6-minute walk distance, quality of life, and functional class. Exercise should be low-to-moderate intensity, supervised initially, and guided by your PH team. Avoid heavy isometric exercise (straining).
• Iron supplementation — Iron deficiency is common in PAH and can worsen symptoms even without anemia. IV iron is preferred when oral iron is not tolerated.
• Vaccination — Influenza, pneumococcal, COVID-19, and RSV vaccines are recommended. Respiratory infections can trigger PAH exacerbations.

Your initial treatment strategy depends on your risk at diagnosis:

• Low or intermediate-low risk: Dual oral combination therapy (ERA + PDE5 inhibitor). The most common starting regimen: ambrisentan + tadalafil (as proven in AMBITION) or macitentan + tadalafil (now available as the single pill Opsynvi). Add sotatercept if WHO FC II–III and on stable background therapy.
• Intermediate-high risk: Triple therapy including a prostacyclin pathway agent. Options: ERA + PDE5i + selexipag (oral, as in TRITON), or ERA + PDE5i + inhaled treprostinil, or ERA + PDE5i + parenteral prostacyclin for sicker patients. Consider early sotatercept addition.
• High risk: Urgent initiation of IV or SC prostacyclin (epoprostenol or treprostinil) plus oral combination therapy (ERA + PDE5i). Early transplant referral. Sotatercept may be added. These patients need care at a PH expert center.
• Vasoreactive-positive: High-dose calcium channel blocker (nifedipine, diltiazem, or amlodipine). Monitor response at 3–6 months. If response is lost, switch to standard combination therapy.

Treatment goal: Achieve and maintain low-risk status. Risk is reassessed at every clinic visit (typically every 3–6 months) using 6-minute walk test, NT-proBNP, functional class, and echocardiography. If you are not reaching low risk, therapy should be escalated.

• What combination of medications are you recommending for me, and why?
• Am I a candidate for sotatercept (Winrevair)? If not now, when might I be?
• What side effects should I watch for with each medication?
• Do I need a prostacyclin infusion? If so, what are the options (IV vs SC vs inhaled)?
• How will we know if my treatment is working?
• What is my goal for 6-minute walk distance and BNP levels?
• Am I on the maximum tolerated doses of all my current medications?
• Are there any drug interactions I need to know about?

• Add sotatercept if not already on it — the ZENITH trial demonstrated significant benefit even in WHO FC III–IV patients on double or triple background therapy.
• Switch to or add parenteral prostacyclin — IV epoprostenol remains the most potent PAH medication and should be considered in any patient not reaching treatment goals. Transitioning from oral/inhaled prostacyclins to continuous IV infusion is a major step but can be transformative.
• Optimize doses — Ensure all medications are at maximum tolerated doses. ERA, PDE5i, and prostacyclin doses should be maximized before concluding treatment failure.
• Reassess diagnosis — Re-evaluate for Group 2 PH (occult left heart disease), CTEPH (potentially curable with surgery), or pulmonary veno-occlusive disease (PVOD). A repeat right heart catheterization may be warranted.

Lung transplantation (bilateral lung or, rarely, heart-lung transplant) is the definitive treatment for PAH that does not respond to medical therapy. Key points:

• Refer early. Transplant evaluation takes months. The ISHLT 2024 guidelines recommend referral when patients remain in intermediate-high or high risk despite maximal medical therapy, when functional class is III–IV despite treatment, or when there are signs of progressive right heart failure.
• Listing criteria — Generally includes cardiac index <2.0 L/min/m², mean right atrial pressure >15 mmHg, 6MWD <350 m, or rapid clinical deterioration despite triple therapy plus sotatercept.
• Bridge to transplant — IV epoprostenol is the primary bridge strategy. ECMO (extracorporeal membrane oxygenation) is used for acute decompensation as a bridge in select centers.
• Post-transplant outcomes — Median survival after bilateral lung transplant for PAH is approximately 5–6 years. Quality of life typically improves dramatically. Lifelong immunosuppression and monitoring are required.
• In Utah: The University of Utah Health is the only adult lung and heart/lung transplant center in the Mountain West region. It is a Pulmonary Hypertension Association (PHA)-accredited Comprehensive Care Center. Contact: 801-213-9069.

Atrial septostomy is a procedure that creates a small hole between the right and left atria of the heart. This allows blood to bypass the blocked lungs and relieve pressure on the failing right heart, at the cost of slightly lower oxygen levels. It is used as a palliative measure or bridge to transplant in patients with refractory right heart failure and recurrent syncope. It should only be performed at experienced PH centers.

The PAH treatment pipeline is the most active it has ever been. Several promising agents are in clinical development:

• Ralinepag — An oral, selective prostacyclin receptor (IP) agonist. The Phase 3 ADVANCE OUTCOMES trial (NCT03626688) met its primary endpoint, showing a 55% reduction in clinical worsening events compared to placebo when added to background PAH therapy. An NDA (new drug application) submission to the FDA is expected in the second half of 2026. If approved, it would be another oral prostacyclin pathway option.
• Seralutinib — An inhaled kinase inhibitor targeting PDGFR, CSF1R, and c-KIT pathways. The Phase 2 TORREY trial (NCT04456998) showed improvements in PVR at 24 weeks. However, the Phase 3 PROSERA trial (NCT05934526, reported February 2026) did not meet its primary endpoint of 6MWD improvement (nominal +13.3 m, not statistically significant). Subgroup analyses suggested a possible signal in CTD-PAH patients. The future development path is uncertain.
• Sotatercept in new settings — The HYPERION trial (NCT04811092) evaluated sotatercept as part of initial combination therapy in recently diagnosed PAH patients (N=320) and met its primary endpoint (time to clinical worsening; HR 0.24, P<0.001). Enrollment was closed early due to accumulating external evidence, and full results were published in NEJM (2025). The SOTERIA open-label extension (NCT04796337) confirmed durability of benefit at 2+ years. Additional studies are exploring sotatercept in pediatric PAH and in earlier-stage disease.

How to find clinical trials:

• ClinicalTrials.gov — Search “pulmonary arterial hypertension” and filter by recruiting, your location, and intervention type.
• PHA (Pulmonary Hypertension Association) — Maintains an active clinical trial finder: phassociation.org/patients/clinical-trials
• Your PH center — Ask your doctor directly about trials available at your center and whether you might qualify.
• University of Utah and Intermountain Health both participate in multicenter PAH clinical trials.

A note on investigational agents: Clinical trials offer access to promising new treatments but are not guaranteed to help. They involve additional monitoring and visits. Discuss risks, benefits, and logistics thoroughly with your PH team before enrolling.

Acute right heart failure is a medical emergency in PAH. Seek immediate care if you experience:

• Sudden worsening of shortness of breath at rest
• Fainting or near-fainting episodes
• Rapid swelling of legs or abdomen
• New or worsening chest pain
• Unable to perform basic activities (getting dressed, walking across a room)
• If on IV prostacyclin: pump malfunction, catheter infection signs (fever, redness at line site), or accidental interruption

Important: Go to an emergency department that has experience with PH if possible. If on IV prostacyclin, NEVER let anyone disconnect your pump unless they understand PAH management. Bring your medication list and your PH center's emergency contact number.

• Am I on maximal medical therapy? If not, what else can be added?
• Should I be referred for transplant evaluation? When is the right time?
• Are there clinical trials I might qualify for?
• What are the signs that I should go to the emergency room?
• If I am on IV prostacyclin, what do I do if the pump malfunctions?
• Would sotatercept be appropriate for my situation?

• Exercise is beneficial — Multiple studies show that supervised, structured exercise training improves exercise capacity, quality of life, and functional class in PAH. The key is appropriate, supervised exercise — not bed rest.
• Start supervised — Ideally in a pulmonary rehabilitation program experienced with PH patients. Typical programs include walking, stationary cycling, light resistance training, and breathing exercises.
• Guidelines: Low-to-moderate intensity, 30 minutes most days. Avoid exercising to the point of severe breathlessness, dizziness, or chest pain. Stop if you feel lightheaded or faint.
• Avoid: Heavy weight lifting or isometric exercise (holding your breath against resistance), competitive sports, exercising in extreme heat, and any activity that causes symptoms of syncope.
• Self-monitoring: The “talk test” — you should be able to hold a conversation during exercise. If you can't, you're pushing too hard.

• Air travel — Cabin altitude in commercial aircraft is equivalent to 6,000–8,000 feet. This reduces available oxygen and can worsen PAH symptoms. Discuss supplemental oxygen for flights with your doctor, even if you don't normally use oxygen.
• High altitude — Avoid prolonged stays above 5,000–6,000 feet if possible. For Utah patients: Salt Lake City sits at approximately 4,300 feet. Patients traveling to higher-elevation Utah destinations (Park City ~7,000 ft, ski resorts 8,000–11,000 ft) should exercise extreme caution and discuss oxygen needs with their PH team in advance.
• Planning: Carry extra medication supplies, your medical records/emergency contacts, and know where the nearest PH-capable hospital is at your destination.
• IV prostacyclin and travel: Coordinate with your specialty pharmacy well in advance for medication supply and pump servicing. Airlines may require medical documentation for carrying infusion pumps and supplies.

• Effective contraception is essential and should be discussed at every visit. IUDs (copper or hormonal) or progestin-only methods are preferred. Combined estrogen-containing pills are generally avoided (thrombotic risk).
• ERAs (ambrisentan, macitentan, bosentan) and sotatercept are teratogenic — they cause birth defects. Monthly pregnancy testing is required while on these drugs.
• If pregnancy does occur, the patient should be managed at a center with expertise in both PH and high-risk obstetrics, with early multidisciplinary planning.

Living with a chronic, life-threatening illness is emotionally demanding. Depression and anxiety are common in PAH patients — studies suggest prevalence rates of 25–40%.

• Seek professional support — Ask your PH team about psychologist or counselor referrals. Many PH centers have integrated mental health support.
• Connect with others — The Pulmonary Hypertension Association (PHA) offers peer support groups, online forums, and mentoring programs matching newly diagnosed patients with experienced patients.
• Acknowledge grief — It is normal to grieve the loss of your pre-diagnosis lifestyle and abilities. This is not weakness; it is a healthy process.
• Stay engaged — Many PAH patients continue to work, travel, and pursue hobbies with appropriate accommodations. Disability accommodations may be available under the ADA.

• Never stop PAH medications abruptly — Especially prostacyclins. Sudden withdrawal can cause rebound pulmonary hypertension crisis. If you cannot take a medication (vomiting, supply issue), contact your PH team immediately.
• Keep a medication list — PAH patients often take 5–10+ medications. A current list with doses and timing should be on your phone and in your wallet.
• Set alarms — Inhaled prostacyclins (Tyvaso, Yutrepia) and oral medications need consistent timing.
• Specialty pharmacy — Most PAH medications are distributed through specialty pharmacies. Build a relationship with your pharmacy team; they can help with insurance authorization, copay assistance, and delivery coordination.
• Emergency supply — Keep at least 48–72 hours of extra medication at home. For IV prostacyclin, ensure you have backup pump supplies and cassettes.

Caring for someone with PAH is demanding physically and emotionally. You are an essential part of the treatment team.

• Learn the medications — Especially prostacyclin infusion management (pump operation, mixing, sterile technique, troubleshooting). Your PH center will train you, but staying current is critical.
• Recognize warning signs — Know what worsening symptoms look like (increased swelling, worsening shortness of breath, fainting, rapid weight gain) and when to call the PH team vs. go to the ER.
• Manage oxygen equipment — If supplemental oxygen is prescribed, learn about the equipment (portable concentrators, tanks), when it's needed, and how to arrange refills.
• Support daily function — Help with medication timing, weight monitoring, activity pacing, and appointment logistics.
• Take care of yourself — Caregiver burnout is real. Seek your own support through the PHA caregiver network, respite care, and counseling. You cannot provide good care if you are depleted.
• Plan ahead — Advance directive discussions, emergency plans, and understanding transplant logistics are important family conversations to have early, not in crisis.

• Sodium restriction — Limit sodium to <2,000 mg/day to help manage fluid retention. Read food labels carefully. Restaurant and processed food are the biggest culprits.
• Fluid management — Your doctor may recommend limiting fluid intake to 1.5–2 liters/day, especially if you have significant edema or hyponatremia.
• Daily weights — Weigh yourself every morning before eating, after using the bathroom, in the same clothing. Report rapid gains (>2 lbs/day or >5 lbs/week) to your PH team.
• Avoid excessive alcohol — Alcohol can lower blood pressure (especially problematic with PAH medications) and affect the liver.
• Infection prevention — Hand hygiene, stay current on vaccinations, avoid close contact with sick individuals. Respiratory infections can trigger PAH exacerbations.

• What level of physical activity is safe for me?
• Do I need supplemental oxygen? At rest, during exercise, or during sleep?
• Can I travel by air? Do I need in-flight oxygen?
• What are the warning signs that I should call your office vs. go to the ER?
• Can you refer me to a mental health professional experienced with chronic illness?
• Are there support groups in my area for PAH patients and caregivers?
• Should I have an advance directive or medical alert identification?

• University of Utah Health — Pulmonary Hypertension Program
  PHA-accredited Comprehensive Care Center. Full-spectrum PH care including right heart catheterization, all approved PAH therapies, clinical trials, and the only adult lung and heart/lung transplant program in the Mountain West region. Phone: 801-213-9069. University of Utah Health main line: 801-581-2121.
  Referral recommended for: All newly diagnosed PAH patients, patients not reaching treatment goals, transplant evaluation, complex cases, and clinical trial interest.
• Intermountain Health — Pulmonary Hypertension Clinic
  PHA-accredited center. Schmidt Chest Clinic, 5121 S Cottonwood St, Murray, UT 84107. Comprehensive PH diagnosis and treatment. Strong collaboration with cardiology and rheumatology for CTD-PAH. Phone: 801-442-2000.
• Primary Children’s Hospital (Intermountain / U of U)
  Pediatric PH program affiliated with the University of Utah. Referral center for children and adolescents with PAH in the Intermountain region. Phone: 801-662-1000.
• University of Colorado — Pulmonary Hypertension Center
  PHA-accredited Comprehensive Care Center in Aurora, CO. Regional referral center for the Mountain West. Altitude-aware PH management. Phone: 720-848-0000.

• Cleveland Clinic — Respiratory Institute, PH Program
  PHA Comprehensive Care Center. One of the largest PH programs in the US. Full spectrum of therapies including transplant. Phone: 216-444-6503.
• Massachusetts General Hospital — Pulmonary Vascular Disease Program
  PHA Comprehensive Care Center. Major clinical trial site. Integrated with MGH transplant program. Phone: 617-726-2000.
• Johns Hopkins — Pulmonary Hypertension Program
  PHA Comprehensive Care Center. Strong scleroderma-PAH program. Phone: 410-955-5000.
• Stanford University — Vera Moulton Wall Center for Pulmonary Vascular Disease
  One of the pioneering PH programs in the US. Lung transplant center. Phone: 650-723-6961.
• UPMC — Pittsburgh Heart, Lung, Blood Vascular Medicine Institute
  PHA Comprehensive Care Center. Major transplant program. Phone: 412-647-8762.
• UT Southwestern — Pulmonary Hypertension Program
  PHA Comprehensive Care Center. Leading clinical research site for PAH trials. Phone: 214-645-8300.

Finding a PHA-accredited center near you: The Pulmonary Hypertension Association maintains a searchable directory of accredited care centers: phassociation.org/patients/doctorsfacilities

• George E. Wahlen VA Medical Center (Salt Lake City)
  Cardiopulmonary division providing PH care for veterans. Referral pathways to University of Utah for advanced therapies and transplant evaluation. Phone: 801-582-1565.
• VA National Referral Network — Veterans can request referral to any VA facility or to a non-VA PHA-accredited PH center through the VA Community Care program if specialized PH services are not available locally.
• VA Ann Arbor Healthcare System — PH Program
  Established VA PH referral center. Phone: 734-769-7100.

Tip for veterans: If your local VA does not have a dedicated PH specialist, request a Community Care referral to the nearest PHA-accredited center. You are entitled to specialized care.

• Toronto General Hospital — Pulmonary Hypertension Programme (University Health Network)
  Canada’s largest PH program. Full spectrum of therapies including transplant (Toronto Lung Transplant Program is one of the world’s largest). Phone: 416-340-4800.
• McGill University Health Centre — PH Clinic (Montreal)
  Comprehensive PH care with strong CTD-PAH program. Phone: 514-934-1934.
• University of Alberta — PH Clinic (Edmonton)
  Western Canada referral center. Lung transplant program. Phone: 780-407-8822.
• St. Paul’s Hospital — PH Program (Vancouver, UBC)
  PH center of excellence. Clinical trials participation. Phone: 604-682-2344.

Canadian PH Association (PHA Canada): phacanada.ca. Support groups, educational resources, and advocacy across Canada.

United Kingdom:

• Royal Papworth Hospital (Cambridge) — UK national PH referral center. Heart-lung transplant centre. Phone: +44 1223 638000.
• Hammersmith Hospital / Imperial College London — National PH service. Phone: +44 20 3313 1000.

Europe:

• Université Paris-Saclay / Hôpital Bicêtre (Paris, France) — World-leading PH center. Hosts the French PH Registry. Home institution for many key ESC/ERS guideline authors.
• University Hospital Giessen (Germany) — Major PH research center. COMPERA registry host. Part of the German PH network (DZL).
• University of Bologna (Italy) — Established PH program with extensive registry data.

Asia-Pacific:

• National Cerebral and Cardiovascular Center (Osaka, Japan) — Leading Japanese PH center. Access to PMDA-approved therapies including beraprost.
• Fuwai Hospital (Beijing, China) — China’s premier cardiovascular center. Major PH research program and national PH registry.

International organizations:

• European Pulmonary Hypertension Association (PHA Europe) — phaeurope.org. Coordinates national PH associations across Europe.
• EMA sotatercept access: Sotatercept was approved by the EMA in August 2024 for all 27 EU member states. Individual country reimbursement timelines vary. Contact your national PH association for access updates.
• Japan and South Korea: PMDA-approved PAH therapies include beraprost, an oral prostacyclin (IP-receptor agonist) approved in both countries but not available in the US or EU. A sustained-release formulation is also marketed. Japan’s healthcare system provides coverage for PAH as a designated intractable disease. Japanese Pulmonary Hypertension Forum: jpah.jp.
• Access challenges in low- and middle-income countries: Many countries have access only to PDE5 inhibitors (sildenafil, tadalafil). IV/SC prostacyclins require infrastructure that may not be available. Sotatercept access outside the US, EU, and Japan may take years. The PHA and WHO are working to improve global access.

• Pulmonary Hypertension Association (PHA) — phassociation.org
  The primary US patient advocacy organization. Offers: support groups (in-person and virtual), clinical trial finder, care center directory, educational resources, PH conferences, patient mentoring, caregiver support. Helpline: 301-565-3004.
• PHA Support Groups — Find local and virtual support groups at phassociation.org/patients/support-groups. Utah has periodic local meetings.
• Team PHenomenal Hope — teamph.org
  Inspires PH patients and raises funds for research. Connects patients with athletic mentors.

PAH medications are expensive — some cost $100,000+ per year. Financial assistance is available:

• Manufacturer patient assistance programs (PAPs) — Most PAH drug manufacturers (Merck/MSD for sotatercept, Janssen for macitentan, United Therapeutics for treprostinil) offer copay cards, patient assistance programs, and specialty pharmacy coordination. Ask your specialty pharmacy or PH nurse to help you apply.
• PHA financial assistance resources — The PHA website lists assistance programs, copay foundations, and travel grants: phassociation.org/patients/insurance-resources
• PAN Foundation, HealthWell Foundation, NORD — Disease-specific copay assistance funds for pulmonary hypertension. Funding availability varies by quarter.
• Social work services — Most PH centers have social workers who specialize in navigating insurance authorization, disability applications, and financial aid.

The figures below are US list or cash prices, for orientation only. What you actually pay depends on your insurance, specialty-pharmacy contracts, and assistance programs. Cash prices change often — confirm current numbers with your specialty pharmacy.

• Sotatercept (Winrevair): Merck set the US list price at approximately $14,000 per vial at its 2024 launch — roughly $238,000 per year for a typical patient dosed every 3 weeks (Merck, reported 2024). Through the Merck Access Program, eligible commercially insured patients may pay as little as $5 per prescription (up to $10,150 per year in savings); uninsured patients may qualify for free medication through the Merck Patient Assistance Program. Patient Navigator: 888-637-2502.
• Selexipag (Uptravi): Brand-only. The cash list price is roughly $15,000–$24,000 for a 60-tablet (about one month) supply depending on strength (GoodRx, July 2026). The manufacturer copay program can bring eligible insured patients to as little as $5–$10 per month.
• Ambrisentan (generic of Letairis): Cash list prices for 30 tablets run into the low thousands of dollars, but a GoodRx or manufacturer discount commonly brings the generic to roughly $270 for a 30-day supply (GoodRx, July 2026).
• Sildenafil (generic Revatio) and tadalafil (generic Adcirca): Now inexpensive generics. Generic sildenafil starts around $10–$15 for a month, and generic tadalafil 20 mg (30 tablets) is about $18 with a GoodRx coupon, versus roughly $1,270 retail (GoodRx, July 2026).

How to afford it (the coverage path): Nearly all PAH-specific drugs are dispensed through specialty pharmacies and require prior authorization; the ERAs and sotatercept also require REMS enrollment. Work this ladder with your PH center's nurse coordinator and social worker: (1) manufacturer copay cards (Merck Access for Winrevair, Johnson & Johnson for Uptravi, United Therapeutics for treprostinil products); (2) independent copay foundations — the PAN Foundation, HealthWell Foundation, and NORD run PAH-specific funds (availability rotates by quarter); (3) the manufacturer's free-drug patient assistance program if you are uninsured; (4) the PHA insurance and financial-assistance resources listed above. Do not abandon a prescribed drug over cost before your center's team has run this ladder.

• Pulmonary Hypertension Association (PHA) — The most comprehensive and reliable patient resource
• ESC/ERS PH Guidelines — Professional guidelines, but freely accessible
• ClinicalTrials.gov — Search for PAH clinical trials
• NIH NHLBI — Basic PAH information from the National Institutes of Health

Caution: Be wary of unverified claims on social media. Herbal and alternative remedies for PAH (including Rhodiola, Dan Shen) have not been proven effective in clinical trials and may interact with PAH medications. Always discuss any supplements with your PH team.

• Aminorex (Menocil) WITHDRAWN
  An appetite suppressant marketed in Europe in the 1960s. It caused an epidemic of PAH in Switzerland, Austria, and Germany. Withdrawn from the market in 1968 after the link was established. Aminorex was one of the first definitive examples of a drug causing PAH and helped establish the field of drug-induced pulmonary hypertension.
• Fenfluramine / Dexfenfluramine (Pondimin / Redux) WITHDRAWN
  Appetite suppressants widely prescribed in the 1990s, often in the “fen-phen” combination (fenfluramine + phentermine). Withdrawn by the FDA in 1997 after causing PAH and heart valve disease. Some patients developed PAH years after stopping the drugs. If you took fen-phen in the past and have unexplained shortness of breath, tell your doctor.
• Routine anticoagulation for all PAH patients DE-ADOPTED
  Warfarin was once recommended for all PAH patients based on small, retrospective studies suggesting a survival benefit. Subsequent registry data (COMPERA, REVEAL) did not confirm a clear benefit for most patients, and showed increased bleeding risk — especially in CTD-PAH with scleroderma gut involvement. Current ESC/ERS 2022 guidelines no longer recommend routine anticoagulation and suggest it should be considered only on a case-by-case basis, primarily in idiopathic PAH.
• Sequential monotherapy (one drug at a time) DE-ADOPTED
  Before the AMBITION trial (2015), the standard approach was to start a single PAH drug and add more only if the patient worsened. AMBITION proved that starting two drugs together (ambrisentan + tadalafil) reduced the risk of clinical failure by 50% compared to monotherapy. Sequential monotherapy is now considered substandard care. If you are being offered a single drug as your only PAH treatment at diagnosis (other than CCBs for the rare vasoreactive patient), ask about combination therapy.
• Calcium channel blockers for non-vasoreactive patients FAILED
  High-dose calcium channel blockers (nifedipine, diltiazem) are effective only in the ~5–10% of idiopathic PAH patients who test positive for vasoreactivity during right heart catheterization. Giving CCBs to non-vasoreactive PAH patients is not only ineffective but potentially harmful — they can cause systemic hypotension and worsen right heart failure. CCBs should never be prescribed for PAH without a documented positive vasoreactivity test.
• Seralutinib (inhaled kinase inhibitor) FAILED
  Seralutinib is an inhaled drug that targets PDGFR, CSF1R, and c-KIT pathways involved in abnormal blood vessel growth. After a promising Phase 2 trial (TORREY), the Phase 3 PROSERA trial (reported February 2026) did not meet its primary endpoint — it did not significantly improve 6-minute walk distance. While subgroup analyses suggested a possible benefit in connective tissue disease-associated PAH, the overall trial was negative. Its future development is uncertain.
• Beraprost (oral prostacyclin — outside Japan/Korea) FAILED
  Beraprost is an oral prostacyclin approved in Japan and South Korea. However, a US/European development program failed to demonstrate sustained clinical benefit beyond 3–6 months in controlled trials. The FDA did not approve it. It remains available and used in Japan and Korea, but is not considered a viable option in the US, Europe, or most other markets.

Why this matters: If you encounter outdated recommendations (for example, starting a single drug, or being prescribed a calcium channel blocker without a vasoreactivity test), these are signals to seek a second opinion at a specialized PH center.